• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎疫苗不良反应:潜在的分子机制。

COVID-19 vaccines adverse events: potential molecular mechanisms.

机构信息

Laboratory of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.

4th Department of Internal Medicine, School of Medicine, Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6.

DOI:10.1007/s12026-023-09357-5
PMID:36607502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9821369/
Abstract

COVID-19 is an infectious disease caused by a single-stranded RNA (ssRNA) virus, known as SARS-CoV-2. The disease, since its first outbreak in Wuhan, China, in December 2019, has led to a global pandemic. The pharmaceutical industry has developed several vaccines, of different vector technologies, against the virus. Of note, among these vaccines, seven have been fully approved by WHO. However, despite the benefits of COVID-19 vaccination, some rare adverse effects have been reported and have been associated with the use of the vaccines developed against SARS-CoV-2, especially those based on mRNA and non-replicating viral vector technology. Rare adverse events reported include allergic and anaphylactic reactions, thrombosis and thrombocytopenia, myocarditis, Bell's palsy, transient myelitis, Guillen-Barre syndrome, recurrences of herpes-zoster, autoimmunity flares, epilepsy, and tachycardia. In this review, we discuss the potential molecular mechanisms leading to these rare adverse events of interest and we also attempt an association with the various vaccine components and platforms. A better understanding of the underlying mechanisms, according to which the vaccines cause side effects, in conjunction with the identification of the vaccine components and/or platforms that are responsible for these reactions, in terms of pharmacovigilance, could probably enable the improvement of future vaccines against COVID-19 and/or even other pathological conditions.

摘要

COVID-19 是一种由单链 RNA(ssRNA)病毒引起的传染病,这种病毒被称为 SARS-CoV-2。自 2019 年 12 月在中国武汉首次爆发以来,该疾病已导致全球大流行。制药行业已经开发出几种针对该病毒的不同载体技术的疫苗。值得注意的是,在这些疫苗中,有七种已被世界卫生组织(WHO)完全批准。然而,尽管 COVID-19 疫苗接种有其好处,但已报告了一些罕见的不良反应,这些不良反应与针对 SARS-CoV-2 开发的疫苗的使用有关,尤其是那些基于 mRNA 和非复制病毒载体技术的疫苗。报告的罕见不良事件包括过敏和过敏性反应、血栓和血小板减少症、心肌炎、贝尔氏面瘫、短暂性脊髓炎、吉兰-巴雷综合征、带状疱疹复发、自身免疫病发作、癫痫和心动过速。在这篇综述中,我们讨论了导致这些罕见不良事件的潜在分子机制,并尝试将其与各种疫苗成分和平台联系起来。根据疫苗引起副作用的潜在机制,结合药物警戒学中确定导致这些反应的疫苗成分和/或平台,可能能够改进针对 COVID-19 甚至其他病理状况的未来疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/f0ab1ed869b3/12026_2023_9357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/a91963d3d98b/12026_2023_9357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/2354ade499ca/12026_2023_9357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/a4b04a008bc5/12026_2023_9357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/f0ab1ed869b3/12026_2023_9357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/a91963d3d98b/12026_2023_9357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/2354ade499ca/12026_2023_9357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/a4b04a008bc5/12026_2023_9357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a1/9821369/f0ab1ed869b3/12026_2023_9357_Fig4_HTML.jpg

相似文献

1
COVID-19 vaccines adverse events: potential molecular mechanisms.新型冠状病毒肺炎疫苗不良反应:潜在的分子机制。
Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6.
2
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.背景 2015 年至 2020 年,加拿大安大略省与 COVID-19 疫苗相关的特殊关注不良事件的基础发病率,用于为 COVID-19 疫苗安全性监测提供信息。
Vaccine. 2022 May 26;40(24):3305-3312. doi: 10.1016/j.vaccine.2022.04.065. Epub 2022 Apr 27.
3
Incidence and management of the main serious adverse events reported after COVID-19 vaccination.报告的 COVID-19 疫苗接种后主要严重不良事件的发生率和处理。
Pharmacol Res Perspect. 2024 Jun;12(3):e1224. doi: 10.1002/prp2.1224.
4
Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review.COVID-19 疫苗接种后的神经免疫相关不良事件:系统评价。
J Clin Pharmacol. 2022 Mar;62(3):291-303. doi: 10.1002/jcph.2017. Epub 2022 Feb 10.
5
Anaphylaxis is a rare reaction in COVID-19 vaccination.在 COVID-19 疫苗接种中,过敏反应较为罕见。
J Biol Regul Homeost Agents. 2021 May-Jun;35(3):839-842. doi: 10.23812/BELLOMO_EDIT_3_21.
6
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗:一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
7
[Allergic reactions to COVID-19 vaccines: evidence and practice-oriented approach].[新型冠状病毒肺炎疫苗的过敏反应:证据与实践导向方法]
Internist (Berl). 2021 Mar;62(3):326-332. doi: 10.1007/s00108-021-00959-5. Epub 2021 Feb 13.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
10
Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel.mRNA COVID-19 疫苗在亚洲军人中的不良反应和安全性概况。
Ann Acad Med Singap. 2021 Nov;50(11):827-837. doi: 10.47102/annals-acadmedsg.2021345.

引用本文的文献

1
COVID-19 Vaccine-Induced Severe Pneumonitis.新冠疫苗诱导的重症肺炎
Respirol Case Rep. 2025 Aug 21;13(8):e70274. doi: 10.1002/rcr2.70274. eCollection 2025 Aug.
2
Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.尼日利亚成年人中新冠病毒疫苗分剂量接种的安全性和免疫原性:一项随机非劣效性试验。
Sci Rep. 2025 Jul 29;15(1):27614. doi: 10.1038/s41598-025-06536-2.
3
Completeness and changes in data reporting pharmacological interventions to treat COVID-19.治疗新冠肺炎的药物干预措施数据报告的完整性与变化情况。

本文引用的文献

1
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.SARS-CoV-2 疫苗的快速开发:拯救世界的疫苗。
Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022.
2
A comprehensive review on Covid-19 Omicron (B.1.1.529) variant.关于新冠病毒奥密克戎(B.1.1.529)变体的全面综述。
Saudi J Biol Sci. 2022 Sep;29(9):103372. doi: 10.1016/j.sjbs.2022.103372. Epub 2022 Jul 15.
3
SARS-CoV-2 Omicron variant: recent progress and future perspectives.SARS-CoV-2 奥密克戎变异株:最新进展与未来展望。
Sci Rep. 2025 Jul 2;15(1):22989. doi: 10.1038/s41598-025-06308-y.
4
Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database.与抗SARS-CoV-2疫苗相关的严重药物不良反应及其在欧洲药品不良反应数据库中的报告趋势
Sci Rep. 2025 May 27;15(1):18582. doi: 10.1038/s41598-025-03428-3.
5
Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation.mRNA加强疫苗接种后对SARS-CoV-2产生有效的细胞免疫和中和免疫与浆细胞样树突状细胞(pDC)和B细胞活化有关。
Front Immunol. 2025 May 12;16:1580448. doi: 10.3389/fimmu.2025.1580448. eCollection 2025.
6
New-onset hematologic disorders following COVID-19 vaccination: a systematic review.新型冠状病毒肺炎疫苗接种后新发血液系统疾病:一项系统综述
Clin Exp Vaccine Res. 2025 Apr;14(2):169-184. doi: 10.7774/cevr.2025.14.e20. Epub 2025 Apr 8.
7
Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance.mRNA新冠疫苗接种后不良事件模式的网络分析:来自欧洲药物警戒数据库EudraVigilance的真实世界数据
Front Med (Lausanne). 2025 Feb 19;12:1501921. doi: 10.3389/fmed.2025.1501921. eCollection 2025.
8
Self-Reported Adverse Events Following COVID-19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross-Sectional Study.在接受症状学培训项目后,医科学生中新冠病毒疫苗接种后的自我报告不良事件:一项横断面研究
Health Sci Rep. 2025 Mar 2;8(3):e70492. doi: 10.1002/hsr2.70492. eCollection 2025 Mar.
9
Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis.伊朗新冠疫苗不良事件报告:一项全面的全国前瞻性纵向分析
Front Immunol. 2025 Feb 14;16:1504973. doi: 10.3389/fimmu.2025.1504973. eCollection 2025.
10
Global burden of vaccine-associated kidney injury using an international pharmacovigilance database.利用国际药物警戒数据库评估疫苗相关肾损伤的全球负担
Sci Rep. 2025 Feb 12;15(1):5177. doi: 10.1038/s41598-025-88713-x.
Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x.
4
SARS-CoV-2 variants and vulnerability at the global level.全球层面的 SARS-CoV-2 变体和脆弱性。
J Med Virol. 2022 Jul;94(7):2986-3005. doi: 10.1002/jmv.27717. Epub 2022 Apr 5.
5
A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson).1剂次Ad26.COV2.S疫苗(杨森/强生公司)接种后发生疫苗诱导的免疫性血小板减少症和血栓形成综合征的病例报告
Therapie. 2022 Nov-Dec;77(6):734-737. doi: 10.1016/j.therap.2022.01.014. Epub 2022 Jan 31.
6
The impact of COVID-19 vaccination on patients with a history of heparin-induced thrombocytopenia.新型冠状病毒肺炎疫苗接种对有肝素诱导的血小板减少症病史患者的影响。
Br J Haematol. 2022 May;197(4):422-423. doi: 10.1111/bjh.18048. Epub 2022 Feb 14.
7
Double Negative (DN) B cells: A connecting bridge between rheumatic diseases and COVID-19?双阴性(DN)B细胞:风湿性疾病与2019冠状病毒病之间的桥梁?
Mediterr J Rheumatol. 2021 Sep 30;32(3):192-199. doi: 10.31138/mjr.32.3.192. eCollection 2021 Sep.
8
Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2.脂质纳米颗粒在与使用抗SARS-CoV-2 mRNA疫苗相关的心肌炎发病机制中的潜在影响。
Metabol Open. 2022 Mar;13:100159. doi: 10.1016/j.metop.2021.100159. Epub 2021 Dec 17.
9
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)疫苗接种与心肌炎或心肌心包炎:基于人群的队列研究
BMJ. 2021 Dec 16;375:e068665. doi: 10.1136/bmj-2021-068665.
10
COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells.新冠病毒疫苗接种偶尔会引发自身免疫现象,可能是通过诱导与年龄相关的B细胞来实现的。
Int J Rheum Dis. 2022 Jan;25(1):83-85. doi: 10.1111/1756-185X.14238. Epub 2021 Nov 12.